Vanguard Group
SYRE icon

Vanguard Group’s Spyre Therapeutics SYRE Stock Holding History

Vanguard Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$132M Buy
4,035,074
+984,344
+32% +$25.7M ﹤0.01% 1739
2025
Q3 		$51.1M Sell
3,050,730
-15,856
-0.5% -$259K ﹤0.01% 2145
2025
Q2 		$45.9M Buy
3,066,586
+168,319
+6% +$2.49M ﹤0.01% 2159
2025
Q1 		$46.8M Buy
2,898,267
+51,794
+2% +$1.08M ﹤0.01% 2114
2024
Q4 		$66.3M Buy
2,846,473
+330,553
+13% +$9.69M ﹤0.01% 2041
2024
Q3 		$74M Buy
2,515,920
+604,354
+32% +$16.8M ﹤0.01% 2017
2024
Q2 		$44.9M Buy
1,911,566
+1,414,385
+284% +$47.7M ﹤0.01% 2191
2024
Q1 		$18.9M Buy
497,181
+457,735
+1,160% +$13.3M ﹤0.01% 2631
2023
Q4 		$849K Buy
39,446
+6,369
+19% +$87.7K ﹤0.01% 3885
2023
Q3 		$405K Buy
33,077
+7,155
+28% +$94.6K ﹤0.01% 4111
2023
Q2 		$292K Sell
25,922
-53,982
-68% -$256K ﹤0.01% 4240
2023
Q1 		$579K Hold
79,904
– – ﹤0.01% 4083
2022
Q4 		$899K Buy
79,904
+4,408
+6% +$79.2K ﹤0.01% 3944
2022
Q3 		$993K Sell
75,496
-2,424
-3% -$29.9K ﹤0.01% 3999
2022
Q2 		$984K Sell
77,920
-6,773
-8% -$237K ﹤0.01% 4096
2022
Q1 		$4.87M Sell
84,693
-132
-0.2% -$11.1K ﹤0.01% 3543
2021
Q4 		$10.1M Buy
84,825
+475
+0.6% +$75K ﹤0.01% 3200
2021
Q3 		$16.8M Buy
84,350
+463
+0.6% +$81K ﹤0.01% 2957
2021
Q2 		$14.6M Sell
83,887
-3,075
-4% -$559K ﹤0.01% 3008
2021
Q1 		$17.2M Buy
86,962
+8,913
+11% +$1.71M ﹤0.01% 2860
2020
Q4 		$15.4M Buy
78,049
+4,071
+6% +$844K ﹤0.01% 2768
2020
Q3 		$13.1M Buy
73,978
+158
+0.2% +$29.2K ﹤0.01% 2654
2020
Q2 		$17.1M Buy
73,820
+26,448
+56% +$5.04M ﹤0.01% 2500
2020
Q1 		$5.52M Buy
47,372
+165
+0.3% +$28.1K ﹤0.01% 2934
2019
Q4 		$9.02M Buy
47,207
+2,037
+5% +$400K ﹤0.01% 2907
2019
Q3 		$8.68M Buy
45,170
+982
+2% +$191K ﹤0.01% 2889
2019
Q2 		$7.57M Sell
44,188
-220
-0.5% -$38K ﹤0.01% 3009
2019
Q1 		$8.94M Buy
44,408
+13,200
+42% +$2.75M ﹤0.01% 2886
2018
Q4 		$5.84M Buy
31,208
+1,087
+4% +$231K ﹤0.01% 3018
2018
Q3 		$7.21M Buy
30,121
+2,207
+8% +$515K ﹤0.01% 3086
2018
Q2 		$7.38M Buy
27,914
+14,417
+107% +$3.55M ﹤0.01% 3050
2018
Q1 		$3.35M Buy
13,497
+2,647
+24% +$478K ﹤0.01% 3291
2017
Q4 		$1.47M Buy
10,850
+4,435
+69% +$543K ﹤0.01% 3514
2017
Q3 		$760K Buy
6,415
+384
+6% +$36K ﹤0.01% 3662
2017
Q2 		$579K Buy
6,031
+519
+9% +$71.8K ﹤0.01% 3698
2017
Q1 		$1.03M Buy
5,512
+3,314
+151% +$468K ﹤0.01% 3572
2016
Q4 		$239K Buy
2,198
+1,613
+276% +$235K ﹤0.01% 3864
2016
Q3 		$94K Buy
+585
New +$81.4K ﹤0.01% 3984

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group's SYRE Position: Q4 2025 in Review

Vanguard Group increased its Spyre Therapeutics (SYRE) stake by 32% in Q4 2025, buying an estimated $25.7M and bringing the position to 4,035,074 shares worth $132M. The position accounts for ﹤0.01% of the portfolio, ranked #1739.

Vanguard Group first reported a position in SYRE in Q3 2016 and has held it in 38 quarters since. 153 funds tracked by Wall St. Rank hold SYRE as of Q4 2025.

  • Vanguard Group held 4,035,074 shares of Spyre Therapeutics worth $132M as of Q4 2025.
  • Vanguard Group bought 984,344 Spyre Therapeutics shares in Q4 2025, an estimated $25.7M.
  • Spyre Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1739 holding.
  • Vanguard Group first reported a position in Spyre Therapeutics in Q3 2016 and has held it in 38 quarters since.
  • 153 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.